MATERIALS LICENSE

Amendment No. 59

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

398511

Licensee	
1. St. Vincent Hospital	In accordance with the application dated April 26, 1995 3. License Number 48-03220-03 is renewed in its entirety to read as follows:
2. 835 South Van Buren Street Green Bay, WI 54307	4. Expiration Date January 31, 2002
	5. Docket or Reference No. 030-03438

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed (not to exceed 1 curie of I-131)
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources identified in 10 CFR 35.500	E. As needed

050056

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-03220-03

Docket or Reference Number
030-03438

Amendment No. 59

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed
G. Americium-241	G. Sealed sources (Amersham/Searle Model No. AMC-24)	G. No single source to exceed 15 millicuries
H. Uranium (Depleted in Uranium-235)	H. Solid Metal	H. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. Medical use described in 10 CFR 35.400.

E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

F. In vitro studies.

G. To be used in Searle Analytic Anatomical Marker Model SS-10244.

H. Shielding in a generator.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 835 South Van Buren Street, Green Bay, Wisconsin.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-03220-03

Docket or Reference Number
030-03438

Amendment No. 59

11. Radiation Safety Officer: Mark Towsley, M.S.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users		Material and Use
A.	Peter A. Fergus, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures).
B.	Timothy J. Freeman, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures) and 35.500.
C.	Matthias A. Fuchs, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures) and 35.500.
D.	Robert Holman, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures).
E.	Ghazwan Katmeh, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures).
F.	Dennis J. Bielke, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
G.	Henry K. Feider, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
H.	Paul R. Bolich, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
I.	Randall K. Kohlhase, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
J.	James E. Robinson, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
K.	Harold E. Stine, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
L.	John H. Randall, M.D.	10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).
M.	Benson L. Richardson, M.D.	10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-03220-03

Docket or Reference Number
030-03438

Amendment No. 59

12. (Continued)

Authorized Users		Material and Use
N.	Michael A. Jacobi, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
O.	Gregory M. Grewe, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 35.500 and 31.11.
P.	Roger C. Wargin, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 35.500 and 31.11.
Q.	Frank M. Weinhold, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma), 35.500 and 31.11.
R.	Ali Mohammadzadeh, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.
S.	Pamela Vanderwall-Lois, M.D.	10 CFR 35.400.
T.	Gregory M. Cooley, M.D.	10 CFR 35.400 and 35.500.
U.	Linda S. Gemer, M.D.	10 CFR 35.400 and 35.500.
V.	Sally M. Schlise, M.D.	10 CFR 35.400 and 35.500.
W.	Raymundo R. Calaguan, M.D.	10 CFR 35.100, 35.200, 35.400, 35.500, 31.11 and phosphorus-32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions.
X.	Mark Towsley, M.S.	10 CFR 400 for survey instrument calibration and 31.11.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-03220-03

Docket or Reference Number
030-03438

Amendment No. 59

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated April 26, 1995; and

B. Letter dated October 15, 1996.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 1/17/97

By Michael F. Webb
Nuclear Materials Licensing Branch, Region III

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02120
STATUS CODE: 2
FEE CATEGORY: 7C
EXP. DATE: 19950531
FEE COMMENTS: 3N 3P DELETED 4/12/90
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: ST. VINCENT HOSPITAL
RECEIVED DATE: 950428
DOCKET NO: 3003438
CONTROL NO.: 398511
LICENSE NO.: 48-03220-03
ACTION TYPE: RENEWAL

2. FEE ATTACHED
AMOUNT: 1400
CHECK NO.: 116528

3. COMMENTS

SIGNED Janet Bell
DATE 5-1-95

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED /V/)

1. FEE CATEGORY AND AMOUNT: 7C $1400.00

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT
RENEWAL V
LICENSE

3. OTHER

SIGNED SC
DATE 5/3/95

RECEIVED
MAY 08 1995
REGION III

Log May 2 III
Remitter
Check No. 116528
Amount $1400.00
Fee Category 7C
Type of Fee Renewal
Date Check Rec'd 5/3/95
Date Completed
By: SC

95 MAY -3 PM 2:03

EXHIBIT 1

NRC FORM 313
(1-84)
10 CFR 30, 32, 33, 34, 35 and 40

U.S. NUCLEAR REGULATORY COMMISSION
APPROVED BY OMB
3150-0120
Expires: 5-31-87

APPLICATION FOR MATERIAL LICENSE

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

FEDERAL AGENCIES FILE APPLICATIONS WITH:

U.S. NUCLEAR REGULATORY COMMISSION
DIVISION OF FUEL CYCLE AND MATERIAL SAFETY, NMSS
WASHINGTON, DC 20555

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS, IF YOU ARE LOCATED IN:

CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, MAINE, MARYLAND, MASSACHUSETTS, NEW JERSEY, NEW YORK, PENNSYLVANIA, RHODE ISLAND, OR VERMONT, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION I
NUCLEAR MATERIAL SECTION B
631 PARK AVENUE
KING OF PRUSSIA, PA 19406

ALABAMA, FLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO RICO, SOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION II
MATERIAL RADIATION PROTECTION SECTION
101 MARIETTA STREET, SUITE 2900
ATLANTA, GA 30323

IF YOU ARE LOCATED IN:

ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION III
MATERIALS LICENSING SECTION
799 ROOSEVELT ROAD
GLEN ELLYN, IL 60137

ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, SOUTH DAKOTA, TEXAS, UTAH, OR WYOMING, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION IV
MATERIAL RADIATION PROTECTION SECTION
611 RYAN PLAZA DRIVE, SUITE 1000
ARLINGTON, TX 76011

ALASKA, ARIZONA, CALIFORNIA, HAWAII, NEVADA, OREGON, WASHINGTON, AND U.S. TERRITORIES AND POSSESSIONS IN THE PACIFIC, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION V
MATERIAL RADIATION PROTECTION SECTION
1450 MARIA LANE, SUITE 210
WALNUT CREEK, CA 94596

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTION.

1. THIS IS AN APPLICATION FOR (Check appropriate item)

- [ ] A. NEW LICENSE
- [ ] B. AMENDMENT TO LICENSE NUMBER _____
- [X] C. RENEWAL OF LICENSE NUMBER 48-03220-03

2. NAME AND MAILING ADDRESS OF APPLICANT (Include Zip Code)

St. Vincent Hospital
835 South Van Buren Street
Green Bay, WI 54307

3. ADDRESS(ES) WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED

835 South Van Buren Street
Green Bay, WI 54307

4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION | TELEPHONE NUMBER

Mark Towsley, M.S., RSO | 414 433-8652

SUBMIT ITEMS 5 THROUGH 11 ON 8½ x 11" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.

5. RADIOACTIVE MATERIAL
a. Element and mass number, b. Chemical and/or physical form, and c. Maximum amount which will be possessed at any one time

6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.

7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE

8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.

9. FACILITIES AND EQUIPMENT

10. RADIATION SAFETY PROGRAM

11. WASTE MANAGEMENT

12. LICENSEE FEES (See 10 CFR 170 and Section 170.31)
FEE CATEGORY 7C | AMOUNT ENCLOSED $1,400.00

13. CERTIFICATION (Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT.

THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT NAMED IN ITEM 2 CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, AND 40 AND THAT ALL INFORMATION CONTAINED HEREIN IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.

WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948, 62 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

SIGNATURE--CERTIFYING OFFICER	TYPED/PRINTED NAME	TITLE	DATE
Robert Bartingale	Robert Bartingale	Assistant Administrator	4-26-1995

14. VOLUNTARY ECONOMIC DATA

a. ANNUAL RECEIPTS
- [ ] < $250K
- [ ] $250K - 500K
- [ ] $500K - 750K
- [ ] $750K - 1M
- [ ] $1M - 3 $M
- [ ] $3 $M - 7M
- [ ] $7M - 10M
- [ ] > $10M

b. NUMBER OF EMPLOYEES (Total for entire facility excluding outside contractors)

c. NUMBER OF BEDS

d. WOULD YOU BE WILLING TO FURNISH COST INFORMATION (dollar and/or staff hours) ON THE ECONOMIC IMPACT OF CURRENT NRC REGULATIONS OR ANY FUTURE PROPOSED NRC REGULATIONS THAT MAY AFFECT YOU? (NRC regulations permit it to protect confidential commercial or financial proprietary information furnished to the agency in confidence)
- [ ] YES
- [ ] NO

FOR NRC USE ONLY

TYPE OF FEE	FEE LOG	FEE CATEGORY	COMMENTS	APPROVED BY

AMOUNT RECEIVED	CHECK NUMBER	DATE

PRIVACY ACT STATEMENT ON THE REVERSE

RECEIVED
APR 28 1995
REGION III

39851

P.O. Box 13508
Green Bay, WI 54307-3508
414 433-8184
FAX 414 431-3168

St. Vincent Hospital

Radiation Oncology
L. Gemer, MD
G. Cooley, MD
S.M. Schlise, MD
P.V. Lois, MD

26 April 1995

Irene Bell
USNRC Region III
799 Roosevelt Road
Glen Ellyn, IL 60137

Ms. Bell

Please accept our application for materials license for renewal. Enclosed are two copies of our application along with the $1,400.00 fee.

If you have any questions regarding our action plan to prevent repeat violations please call me, Mark Towsley, at 414 433-8652.

Mark Towsley

Mark Towsley, M.S., DABR
Medical Physicist
RSO

Robert Bartingale

Robert Bartingale
Assistant Administrator
St. Vincent Hospital

Attachment 1

Item 5 - Radioactive Material Item 6 - Purpose

Byproduct Material	Amount	Purpose
5.a Material in 35.100	As needed	6.a Medical use
5.b Material in 35.200	As needed	6.b Medical use
5.c Material in 35.300	As needed	6.c Medical use
5.d Material in 35.400	As needed	6.d Medical use
5.e Material in 35.400	150 mCi Sr-90	6.e Medical use
5.f Material in 35.400	350 mCi Gd-153	6.e Medical use
5.g Material in 35.500	As needed	6.f Medical use
5.h Material in 35.11	As needed	6.d Medical use

ATT 7.1.1

Authorized User Previous License 48-03220-03

Ali Mohammadzadeh, M.D.

5.a Material in 35.100
5.b Material in 35.200
5.c Material in 35.300
5.f Material in 35.400 — ? (NC)
5.g Material in 35.500
5.h Material in 35.11

ATT 7.1.2

Authorized User Previous License 48-03220-03

Raymundo Calaguan, M.D.

5.a Material in 35.100
5.b Material in 35.200
5.d Material in 35.400
5.e Material in 35.400
5.f Material in 35.400
5.g Material in 35.500
5.h Material in 35.11 Also Phosphorus-32 as colloidal chromic phosphate for intercavitary treatment of malignant effusion

ATT 7.1.3

Authorized User Previous License 48-03220-03

John H. Randall, M.D.

5.c Material in 35.300
(Excluding Iodine 131 for Thyroid Carcinoma)

ATT 7.1.4

Authorized User Previous License 48-03220-03

Benson L. Richardson, M.D.

5.c Material in 35.300
(Excluding Iodine 131 for Thyroid Carcinoma)

ATT 7.1.5

Authorized User Previous License 48-03220-03

Matthias A. Fuchs, M.D.

5.b Material in 35.200
(Limited to cardiovascular Clinical Procedures)
5.g Material in 35.500

ATT 7.1.6

Authorized User Previous License 48-03220-03

Roger C. Wargin, M.D.

5.a Material in 35.100
5.b Material in 35.200
5.c Material in 35.300
(Excluding Iodine 131 for Thyroid Carcinoma)
5.g Material in 35.500
5.h Material in 35.11

ATT 7.1.7

Authorized User Previous License 48-03220-03

Sally M. Schlise, M.D.

5.d Material in 35.400
5.e Material in 35.400
5.g Material in 35.500

OK

ATT 7.1.8

Authorized User Previous License 48-03220-03

Timothy J. Freeman, M.D.

5.b Material in 35.200 (OK)
(Limited to cardiovascular Clinical Procedures)

35.500?

ATT 7.1.9

Authorized User Previous License 48-03220-03

Peter A Fergus, M.D.

5.b Material in 35.200 (04)
(Limited to cardiovascular Clinical Procedures)

ATT 7.1.10

Authorized User Previous License 48-03220-03

Harold E. Stine, M.D.

5.a Material in 35.100
5.b Material in 35.200 OK
5.g Material in 35.500
5.h Material in 35.11

ATT 7.1.11

Authorized User Previous License 48-03220-03

Randall K. Kohlhase, M.D.

5.a Material in 35.100
5.b Material in 35.200
5.g Material in 35.500
5.h Material in 35.11

ATT 7.1.12

Authorized User Previous License 48-03220-03

Gregory M. Grewe, M.D.

5.a Material in 35.100 (or)
5.b Material in 35.200
5.c Material in 35.300
(Excluding Iodine 131 for Thyroid Carcinoma)
5.g Material in 35.500
5.h Material in 35.11

ATT 7.1.13

Authorized User Previous License 48-03220-03

Frank M. Weinhold. M.D.

5.a Material in 35.100
5.b Material in 35.200
5.c Material in 35.300
(Excluding Iodine 131 for Thyroid Carcinoma)
5.g Material in 35.500
5.h Material in 35.11

ATT 7.1.14

Authorized User Previous License 48-03220-03

Linda S. Gemer, M.D.

5.d Material in 35.400
5.e Material in 35.400
5.g Material in 35.500

ATT 7.1.15

Authorized User Previous License 48-03220-03

Gregory M. Cooley, M.D.

5.d Material in 35.400
5.e Material in 35.400
5.g Material in 35.500

ATT 7.1.16

Authorized User Previous License 48-03220-03

Robert Holman, M.D.

5.b Material in 35.200 (04)
(Limited to cardiovascular Clinical Procedures)

ATT 7.1.17

Authorized User Suppliment A Attached

Pamela Lois. M.D.

5.d Material in 35.400
5.e Material in 35.400
5.g Material in 35.500

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Pamela Lois, MD	Wisconsin

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
Radiology ACR		1992

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE

ATT 7.1.18

Authorized User Suppliment A Attached

Ghazwan Katmah. M.D.

5.b Material in 35.200
(Limited to cardiovascular Clinical Procedures)

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Ghazwan Katmeh, MD	Wisconsin

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
Internal Medicine		1988
Cardiovascular Disease		1993

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE

ATT 7.1.19

Authorized User Suppliment A Attached

Henry Feider, M.D.

5.a Material in 35.100
5.b Material in 35.200
5.c Material in 35.300
(Excluding Iodine 131 for Thyroid Carcinoma)
5.g Material in 35.500
5.h Material in 35.11

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Henry Feider, MD	Wisconsin

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
Diagnostic Radiology		1992

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE

ATT 7.1.20

Authorized User Suppliment A Attached

Dennis Bielke. M.D.

5.a Material in 35.100 (✓b)
5.b Material in 35.200
5.c Material in 35.300
(Excluding Iodine 131 for Thyroid Carcinoma)
5.g Material in 35.500
5.h Material in 35.11

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Dennis Bielke, MD	Wisconsin

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
Radiology		1991

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE

ATT 7.3.1

RSO
Mark Towsley, M.S. Previous License 48-03220-03

5.a Material in 35.100
5.b Material in 35.200
5.c Material in 35.300
5.d Material in 35.400
5.e Material in 35.400
5.f Material in 35.400
5.g Material in 35.500
5.h Material in 35.11

ATT 8.1

ST. VINCENT HOSPITAL
GREEN BAY, WISCONSIN

TRAINING PROGRAM
NUCLEAR MEDICINE DIVISION
DEPARTMENT OF RADIOLOGY

Our training program is [illegible] the model training program that was published in appendix A of the Regulatory Guide 10.8, Revision 2.

8 (a) Nuclear Medicine Personnel

All Nuclear Medicine technologists are certified in Nuclear Medicine technology by the ARRT. Initial orientation involves a nuclear medicine technologist regarding procedures, radiation safety precautions, etc. The RSO gives a refresher program at least once a year. Radiation safety procedures, changes in NRC regulations, license conditions and emergency procedures are reviewed. If a significant change in licensing conditions, regulations or duties were to occur, a special in-service program is held.

8 (b) Nursing Personnel

All patients undergoing therapeutic radionuclide procedures are housed in one nursing station. The nurses in this station receive a minimum of one hour inservice program with the RSO, radiation oncologist and Nuclear Medicine physician annually in the form of lectures. Additionally, the head nurse or assistant head nurse reviews the hospital radiation precaution with new personnel before they work with patients under treatment with radioactive material.

8 (c) Housekeeping personnel on the nursing floor do not come into contact with patients under treatment with radioactive material. Housekeeping personnel do not enter the Nuclear Medicine section during normal working hours. They clean at night after all radioactive material is secured out of their way. Senior housekeeping personnel reviews the precaution area. Annual refresher training is in the form of a memorandum by the RSO.

8 (d) Security Personnel

Security personnel receive refresher training in the form of memorandum. They are instructed to accept delivery of packages containing radioactive material that arrives during other than normal working hours. They were to take the material to the Nuclear Medicine Department and lock it up. If the package appears to be damaged, they are instructed to contact either the RSO, Nuclear Medicine technologist on call or the Chief of Nuclear Medicine. The carrier will be asked to remain at the hospital until it can be determined that neither the driver nor the delivery vehicles is contaminated.

Nuclear Medicine staff shall go through and complete a department orientation form during their 90-day probationary period.

/lmb
Revised May 15, 1991

ATT 9.1.1



FIG. 1 ROOM 125B BRACHYTHERAPY SOURCE STORAGE AND PREPARATION

ATT 9-12



FIG. 2 ROOM 125A

STORAGE
FOR NUC. MEDICINE
LOCKED DOOR



ST. VINCENT HOSPITAL, GREEN BAY WISCONSIN

ATT 9.2

We either send out the survey instruments to an ADCL for calibration or establish and implement the model procedure for calibrating survey instruments. In either case they will follow the model procedure in appendix B published in the guide 10.8, Revision 2.

ATT 9.3

We will establish and implement the model procedure in appendix C published in the guide 10.8, Revision 2.

ATT 9.4

We will establish and implement the model procedure in appendix D published in the guide 10.8, Revision 2.

ATT 9.5

NA

ATT 9.6

NA

ATT 10.1

We will establish and implement the model Radiation Safety Committee Charter and Radiation Safety Officer Delegation of Authority in appendix F published in the guide 10.8, Revision 2.

ATT 10.2

We will establish and impalement the model ALARA in appendix G published in the guide 10.8, Revision 2.

ATT 10.3

We will establish and impalement the model procedure for leak testing Sealed sources in appendix H published in the guide 10.8, Revision 2.

ATT 10.4

We will establish and impalement tne model safety rules in appendix I published in the guide 10.8, Revision 2.

ATT 10.5

We will establish and impalement the model spill procedure in appendix J published in the guide 10.8, Revision 2.

ATT 10.6

We will establish and impalement the model guidance for ordering and receiving radioactive material in appendix K published in the guide 10.8, Revision 2.

ATT 10.7

We will establish and impalement the model procedure for opening packages in appendix L published in the guide 10.8, Revision 2.

ATT 10.8

We will establish and impalement the model procedure for unit dosage record in appendix M1 published in the guide 10.8, Revision 2.

ATT 10.9

We will establish and impalement the model procedure for multidose vial system in appendix M2 published in the guide 10.8, Revision 2.

ATT 10.10

We will establish and impalement the model procedure for measuring and recording molybdenum concentration in appendix M3 published in the guide 10.8, Revision 2.

ATT 10.11

We will establish and impalement the model procedure for keeping am inventory [f implant sources in appendix M4 published in the guide 10.8, Revision 2.

ATT 10.12

We will establish and impalement the model procedure for area surveys in appendix N published in the guide 10.8, Revision 2.

ATT 10.13.1

We will collect spent gas in a shielded container and will establish and implement a procedure for checking a trap effluent in appendix O3 published in the guide 10.8, Revision 2.

ATT 10.13.2

We will follow the model procedure for calculating worker dose from aerosols in appendix O1 published in the guide 10.8, Revision 2.

ATT 10.13.3

We will not directly vent spent aerosols and gases to the atmosphere and therefore no effluent estimation is necessary.

ATT 10.13.4

We will calculate spilled gas clearance times in appendix O4 published in the guide 10.8, Revision 2.

ATT 10.14

We will establish and impalement the model procedure for radiation safety during radiopharmaceutical in appendix P published in the guide 10.8, Revision 2.

ATT 10.15

We will establish and impalement the model procedure for radiation safety during implant therapy in appendix Q published in the guide 10.8, Revision 2.

ATT 11.1

We will establish and impalement the model procedure for radioactive waste disposal in appendix R published in the guide 10.8, Revision 2.

JAN 2 1 1997

Joseph Neidenbach, President
St. Vincent Hospital
835 South Van Buren Street
Green Bay, WI 54307

Dear Mr. Neidenbach:

This refers to your application dated April 26, 1995, and to our telephone conversation with Mr. Mark Towsley of your staff on January 13, 1997.

Enclosed is Amendment No. 59, renewing your NRC Material License No. 48-03220-03 in accordance with your request.

As discussed with Mr. Towsley, please be advised that Drs. Bielke and Feider's certifications in Diagnostic Radiology by the American Board of Radiology do not satisfy the requirements of 10 CFR 35.930(a); therefore, they have not been listed as authorized users of material in 10 CFR 35.300. In order for us to authorize Drs. Bielke and Feider as users of 35.300 material on this license, you will need to submit documentation of their training and experience pursuant to 10 CFR 35.930(b)(2). This training and experience must have been obtained within five years preceding the date of the application, or Drs. Bielke and Feider must have had related continuing education and experience since the required training and experience was completed (see 10 CFR 35.972). Please submit this information on Supplement B forms (enclosed), and, in order to avoid an additional fee, state that the information is additional information to Control Number 398511.

In addition, the following deficiencies in your Quality Management Program (QMP) dated July 25, 1994 were noted:

1. 10 CFR 35.32(a)(5) requires that any unintended deviation from the written directive be identified and evaluated, and appropriate action be taken. Your QMP does not include policies and procedures to institute corrective actions to be taken after any unintended deviation has been identified. Please incorporate such policies and procedures in your QMP (nuclear medicine and radiation oncology).

2. 10 CFR 35.32(d)(2) requires a licensee to retain each written directive, and each record of each administered radiation dose or radiopharmaceutical dosage where a written directive is required, in an auditable form, for three years after the date of administration. Please incorporate such a policy in your QMP (nuclear medicine and radiation oncology).

398511

Per 10 CFR 35.32(e), these requested modifications to your QMP should be sent to the USNRC, Region III, within 30 days after the modifications have been made. This correspondence, as with all correspondences concerning your QMP, should be sent to NRC under separate cover from any licensing correspondence.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC, in writing, within 30 days:

   a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or

   b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).

3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

4. Request and obtain a license amendment before you:

   a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;

   b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;

   c. Change Radiation Safety Officers;

   d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;

e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or

f. Change ownership of your organization.

5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Michael F. Weber
Nuclear Materials Licensing Branch

License No. 48-03220-03
Docket No. 030-03438

Enclosure: Amendment No. 59

DOCUMENT NAME: M:\03003438.CL7
To receive a copy of this document, indicate in the box: "**C**" = Copy without attachment/enclosure "**E**" = Copy with attachment/enclosure "**N**" = No copy

OFFICE	DNMS/RIII	E							
NAME	MFWeber:brt								
DATE	01/17/97								

OFFICIAL RECORD COPY

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351
630-829-9887 (phone), 630-515-1259 (fax)

CONVERSATION RECORD

TIME	DATE
11:20	1/13/97

NAME OF PERSON(S) CONTACTED	ORGANIZATION (OFFICE, DEPT., ETC.)	TELEPHONE NO.
Mark Towsley, RSO	St. Vincent Hospital	414-433-8652

SUBJECT

Questions about 4/26/95 renewal application and 10/15/96 response letter (Control No. 398511)

SUMMARY

Q1: For Drs. Freeman and Katmeh, the renewal application does not request 35.100, the response letter does request 35.100. Are these doctors cardiologists? Are you requesting 35.100?

A1: They are cardiologists, and we are not requesting 35.100.

Q2: For Drs. Bielke and Feider, are you requesting 31.11?

A2: Yes.

Q3: For Drs. Bielke and Feider, are you requesting 35.300? If so, you must provide additional info, as each doctor is only board certified in Diagnostic Radiology by ABR, which doesn't satisfy 35.930.

A3: Unsure.

[I indicated that I would not grant 35.300 at this time, and this would be explained in the cover letter. Mark said that was fine.]

ACTION REQUIRED

Issue renewal with restrictions as stated above.

NAME OF PERSON DOCUMENTING CONVERSATION	SIGNATURE	DATE
Michael F. Weber	Michael F. Weber	1/13/97

Michael Weber
Nuclear Materials Licensing Branch
U. S. Nuclear Regulatory Commission Region III
801 Warrenville Road
Lisle, IL 60532-4351

Date: 15 October 1996
License:48-03220-03
Docket: 030-03438
Control Number 398511

Dear Mr. Weber,

In response to your license review letter dated September 18, 1996, I would like to clarify the following items addressed in the same order.

1. Authorized Materials.

   A. Please limit our I-131 possession to 1 curie.

   B. We posses Am-241 sealed source for use in Searle Analytical Markers. I see now where 35.500 does not specifically identify Am-241 as a 35.500 group except in a bone mineral densitometer.

   C. We currently do not use Depleted Uranium in our Mo99-Tc99m generators, however, should we change companies, we would like to freedom to posses depleted Uranium as needed for Mo99-Tc-99m generators.

2. Authorized Users.

   A. Authorized user Mark Towsley, M.S., for materials in 35.400 for instrument calibrations and 31.11.

   B. Authorized user Dr. Ali Mohammadzadeh for use of 35.100, 35.200, 35.300, 35.500, and 31.11.

   C. Authorized user Dr. Freeman for use of 35.100, 35.200, and 35.500.

   D1. Authorized user Dr. Pam Vanderwall -Lois (legal name change from Lois) for use of 35.400. Enclosed is Dr. Pam Vanderwall -Lois's ABR certificate.

   D2. Authorized user Dr. Katmeh for use of 35.100, and 35.200. Dr. Katmeh is an authorized user on License 48-26090-01

   D3. Authorized user Dr. Feider for use of 35.100, 35.200, 35.300, and 35.500. Enclosed is Dr. Feider's ABR certificate.

D4. Authorized user Dr. Bielke for use of 35.100, 35.200, 35.300, and 35.500. Enclosed is Dr. Bielke's ABR certificate.

D5. Authorized user Dr. Michael Jacobi for use of 35.100, 35.200, and 35.300, (excluding I-131 for thyroid carcinoma therapy). Dr. Jacobi is an authorized user on license 48-10251-01.

E. Since I have these included in our original application I assume that they did not make the copy. Please include the following physicians on our renewal which are on our present license:

Paul R. Bolich, M.D.
James E. Robinson, M.D.

3. License Conditions.

A. We are no tasking for any deviations from manufactures specified radiation safety and handling instructions.

B. We are not asking for any exemptions to Part 20 for radiation levels to the public. These were a part of our license prior to revision to Part 20.

Respectfully Submitted,

Mark Towsley

Mark Towsley, M.S., ~~DABR~~
Medical Physicist, RSO

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine
Hereby certifies that

Henry K. Feider, M.D.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology
On this ninth day of November, 1992
Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Diagnostic Radiology

THE AMERICAN BOARD OF RADIOLOGY
INCORPORATED IN THE DISTRICT OF COLUMBIA
1934

AMERICAN BOARD OF MEDICAL SPECIALTIES

Leal Rogers M.D. President
Lester J. Peters Secretary-Treasurer
Kenneth K. Goodenough M.D. Executive Director

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology,
and the Association of University Radiologists
Hereby certifies that

Dennis James Bielke, M.D.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology

On this sixth day of June, 1991

Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Diagnostic Radiology

THE AMERICAN BOARD OF RADIOLOGY
INCORPORATED IN THE DISTRICT OF COLUMBIA
1934

President

Douglas Maynard MD
Secretary-Treasurer

Kenneth L. Hubbard MD
Executive Director

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine
Hereby certifies that

Pamela Vanderwall Lois, M.D.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology
On this fourth day of June, 1992
Thereby demonstrating to the satisfaction of the Board
that she is qualified to practice the specialty of
Radiation Oncology

THE AMERICAN BOARD OF RADIOLOGY
INCORPORATED IN THE DISTRICT OF COLUMBIA
1934

AMERICAN BOARD MEDICAL SPECIALTIES

President — Secretary-Treasurer — Executive Director

NRC FORM 374
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 03

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated June 15, 1994
1. Peter A. Fergus, M.D.	3. License number 48-26090-01 is amended in its entirety to read as follows:
2. 519 South Monroe Avenue Green Bay, WI 54301	4. Expiration date February 28, 1995
	5. Docket or Reference No. 030-31419

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding xenon-133)	B. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding xenon-133).

CONDITIONS

10. Location of Use: 519 South Monroe Avenue, Green Bay, Wisconsin 54301 and 1727 Shawano Avenue, Green Bay, Wisconsin 54303.

11. Radiation Safety Officer: Peter A. Fergus, M.D.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
48-26090-01

Docket or Reference number
030-31419

Amendment No. 03

12. Authorized User:

A. Peter A. Fergus, M.D., for material in 10 CFR 35.100 and 35.200 (excluding xenon-133) limited to cardiovascular clinical procedures.

B. Ghazwan Katmeh, M.D., for material in 10 CFR 35.100 and 35.200 (excluding xenon-133) limited to cardiovascular clinical procedures.

13. The licensee shall maintain records of information important to safe and effective decommissioning at the address in License Condition 10. per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

14. The licensee shall follow the procedures outlined in Appendix M.3 of Reg. Guide 10.8 (August 1987) when performing molybdenum concentration tests on Tc-99m elutions or extractions.

15. This license is based on the licensee's statements and representations listed below:

A. Application dated December 4, 1989.

B. Letters dated January 29, 1990, June 28, 1991, June 15, 1994; and

C. Letter received June 4, 1990.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 8/3/94

By James Mullauer
Materials Licensing Section, Region III

NRC FORM 374
(10-89) *

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 31

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Holy Family Memorial Medical Center	In accordance with letter dated June 20, 1995, 3. License number 48-10251-01 is amended in its entirety to read as follows:
2. 2300 Western Avenue Manitowoc, WI 54220	4. Expiration date August 31, 1999
	5. Docket or Reference No. 030-03467

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any byproduct material identified in 10 CFR 31.11	D. Prepackaged Kits	D. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. In vitro studies.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
48-10251-01

Docket or Reference number
030-03467

Amendment No. 31

CONDITIONS

10. A. Licensed material shall be received, stored, and used at the licensee's facility located at 2300 Western Avenue, Manitowoc, Wisconsin.

B. Licensed material listed in 10 CFR 35.100 and 35.200 (excluding generators and xenon-133) may be used at temporary job sites of medical care facilities anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material.

11. Radiation Safety Officer: Todd J. Schroeder, M.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Michael A. Jacobi, M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
Thomas A. Keller	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
Raymundo R. Calaguan, M.D.	10 CFR 35.100, 35.200, 31.11 and phosphorus-32 for therapy.
Stephen Dudek, M.D.	10 CFR 35.100 and 35.200.
Todd J. Schroeder, M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
Gregory B. Kapala, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC Form 374A (5-84)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 3 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
48-10251-01

Docket or Reference number
030-03467

Amendment No. 31

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 15, 1994; and

B. Letters dated July 17, 1990 and December 5, 1990 (with attachments).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 6 July 1995

By William P. Reichhold
Materials Licensing Section, Region III

SEP 18 1996

Mark Towsley
Radiation Safety Officer
St. Vincent Hospital
835 South Van Buren Street
Green Bay, WI 54307

Dear Mr. Towsley:

We have reviewed your renewal application dated April 26, 1995, and find that we need additional information, as follows.

1. Authorized Materials

   A. Current NRC policy requires a possession limit of one curie for I-131. This will be applied to your license unless you provide adequate justification for a possession limit greater than one curie.

   B. Your current license authorizes the possession and use of Am-241 sealed sources for use in Searle Analytic Anatomical Markers. However, in your application you have not requested authorization to possess and use Am-241 sealed sources. Please clarify.

   C. Your current license authorizes the possession and use of depleted uranium contained as shielding material in Mo-99/Tc-99m generators. Please indicate if this authorization is still applicable to your program.

2. Authorized Users

   A. You requested authorization for materials in 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500, and 35.11 (I assume 31.11 is meant) for yourself. However, your current license only authorizes you for 35.400 materials for instrument calibrations. Please clarify.

   B. You requested authorization for materials in 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500, and 31.11 for Dr. Mohammadzadeh. Be aware that Dr. Mohammadzadeh is not authorized for 35.400 materials under your current license. Please clarify.

   C. You requested authorization for materials in 10 CFR 35.200 for Dr. Freeman. However, your current license authorizes Dr. Freeman for 35.200 and 35.500 materials. Please clarify.

D. You requested that Drs. Lois, Katmah (or Katmeh?), Feider, and Bielke be listed as Authorized Users. However, you have not provided adequate evidence of the training and experience required by 10 CFR 35 Subpart J. Therefore, for each of the physicians listed above, please submit adequate evidence of the training and experience required by 10 CFR 35 Subpart J by providing one of the following:

a. completed Supplement A and Supplement B (preceptor statement) forms (enclosed). (Supplements A and B need not be submitted if the physician is currently listed on a license as specified in b. below or has received board certification as specified in c. below); or

b. a copy of an NRC or Agreement State license that authorizes the physician for the uses being requested; or

c. a copy of the physician's board certification from the American Board of Radiology, American Board of Nuclear Medicine, American Osteopathic Board of Radiology, British Fellow of the Faculty of Radiology, British Fellow of the Royal College of Radiology, or Canadian Royal College of Physicians.

Please note that if any of the documents in a., b. or c. above reference training and experience which was received more than five years ago, evidence of recentness of training in accordance with 10 CFR 35.972 must also be submitted.

E. The following physicians are listed as Authorized Users on your current license, but are not included in your renewal application. Please clarify.

Lorenzo R. Cruz, M.D.
Paul R. Bolich, M.D.
James E. Robinson, M.D.
Paul J. Zdybel, M.D.

3. License Conditions

A. Your current license authorizes the use of iridium-192 as seeds encased in nylon ribbon and palladium-103 as a sealed source in seeds for topical, interstitial, and intracavitary treatment of cancer. In addition, the license authorizes the licensee to deviate from the manufacturer's radiation safety and handling instructions to the extent that the instructions are not applicable to the type of use proposed by the licensee. However, in the renewal application, you have not requested these authorizations. Please clarify.

B. Your current license authorizes the following maximum radiation levels in the following unrestricted areas:

Maximum Radiation Level	Unrestricted Area
5 mR/hr for less than house 60 hours	Rooms adjacent to rooms which patients treated with brachytherapy sources

However, in the renewal application, you have not requested this authorization. Please clarify. Be aware that the revised Part 20 requires that: (1) the total effective dose equivalent to individual members of the public not exceed 100 mrem in a year, and (2) the dose in any unrestricted area from external sources not exceed 2 mrem/hr in any one hour (see 10 CFR 20.1301).

We will continue our review of your application upon receipt of this information. Please reply in duplicate, within 30 days, and refer to Control Number 398511.

If you have any questions or require clarification on any of the information stated above, you may contact us at (630) 829-9887.

Sincerely,

Original Signed By
Michael F. Weber
Nuclear Materials Licensing Branch

License No. 48-03220-03
Docket No. 030-03438

DOCUMENT NAME: M:\03003438.DF6
To receive a copy of this document, indicate in the box: "C" = Copy without enclosures "E" = Copy with enclosures "N" = No copy

OFFICE	DNMS/RIII	C								
NAME	MWEBER:jaw									
DATE	09/17/96									

OFFICIAL RECORD COPY

May 2, 1995

St. Vincent Hospital
Department of Radiology
ATTN: Mark Towsley
Radiation Safety Officer
835 South Van Buren Street
Green Bay, WI 54307-3508

SUBJECT: LICENSE RENEWAL APPLICATION

Dear Mr. Towsley:

This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.

Any correspondence regarding the renewal application should reference the control number specified and your license number.

Sincerely,

Original Signed By
Marianne Meenan, Chief
Nuclear Materials Support Section

License No. 48-03220-03
Control No. 398511

DOCUMENT NAME: M:\03003438.DT5
To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DRSS/RIII	N							
NAME	MMEENAN:brt	MM							
DATE	05/2/95								

OFFICIAL RECORD COPY